Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.
about
Therapeutic drug monitoring of antiretrovirals for people with HIVA randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.The investigation of patients with HIV infection: 10 years of progress.Clinical evaluation of a dried blood spot assay for atazanavirHIV chemotherapy.The role of therapeutic drug monitoring in treatment of HIV infection.Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Principles and practice of HIV-protease inhibitor pharmacoenhancement.Clinical pharmacology and pharmacokinetics of amprenavir.A critical evaluation of the therapeutic range of indinavir.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice.Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?Early factors in successful anti-HIV treatment.Clinical management of HIV drug resistance.Genotype, phenotype, and virtual phenotype: who needs what and why?Initial therapy for human immunodeficiency virus: broadening the options.The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjectsWeight related differences in the pharmacokinetics of abacavir in HIV-infected patients.A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapyQuality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationAvoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
P2860
Q24239932-A0F7527C-4FAF-443E-B9F3-9F7070044213Q33559216-12576367-D29C-413F-A1D2-BAC06C8504AFQ33622168-7D11A029-BBB9-4B4F-90FE-0136A7F937E6Q33623024-1A857E5A-999D-4A36-AB8D-3BF0813EAFE0Q33769950-57FD7570-21D6-4892-A65C-8178CBBD4FFAQ34112020-1EA9AEB2-C0C8-41A0-8D86-4EE2B0187FAFQ34114808-2C34C800-C72E-4A12-8D44-72616A7960ABQ34140661-E77B0EF2-7286-4699-912B-5D13830EAFF2Q34150893-EDA35EA6-42BE-41FD-B8B7-539C220CF386Q34223088-B89D7160-F038-47C1-A104-6715152291EEQ34229283-59288AD5-B08B-4F3F-9A99-A76F053FBE3AQ34253139-95F801B9-35A7-4A0E-94B4-74637B62FBADQ34459378-5294D34F-9A77-4244-9EA3-C78DA2F6CB9EQ34509359-D2DC899C-F3BD-4CF8-8538-8C1C22EC4BA1Q34709881-7BA9FE57-4708-4702-9385-7FAD907429F7Q34720072-7A45DE91-B984-40D3-9C43-B67DED8FFE97Q34725556-4C2FF9B2-1685-4096-98E7-02E71B664FF3Q35013781-CCA072E2-6F60-4FF7-9339-D73ADAFB66C3Q35014914-1A1C3BC3-57E5-4FB4-9FF4-9C4F915E1E9BQ35058068-7343ED4A-0089-4F4E-844C-A19952D38AD6Q35207282-379BBDAD-CBE9-4AB0-ADBF-DA1898CF6769Q35261045-451027B0-341B-4425-AA05-AEA9C1A973F9Q35676512-361D6089-16EA-46B0-8DE6-4A8296C6BC53Q35759609-BCB4C6F0-E0E0-444B-A3C1-57A424EB626CQ35804001-6286F031-F359-482E-933B-0B26324F49E3Q35826691-A560A7DD-C74C-43FA-868E-3BD82ED66FC8Q35894312-1D10E40D-BBF9-4022-B279-BD60A98B6453Q36376533-C7E42566-DC7B-4A68-8394-5E414937C24BQ36489794-EA762EA9-7C36-4149-A045-C3B1C95B6B53Q36491759-47D543E2-CE3E-4BDC-B01B-E95B14C5E032Q36667227-887E3C13-E48D-428F-93E9-B1E819E01D4DQ37298637-D226B19C-22ED-4949-AC50-5A4AD0447E45Q37313166-12F9D8A4-DCC1-4955-BA79-DABE57EF40A0Q37489345-E573B2E2-E84D-4C4C-9274-0D959CA43325Q38213320-67F6184F-79D8-4448-9C84-ECC2DE6DFFD2Q38954109-6F223BBB-7F92-46CD-A4E0-5894304C5136Q39748924-45EEFF54-DADF-4126-AF90-B694D9DEDFD9Q40131713-82DCBE18-7578-41E1-823B-946AEDF73ACCQ42662196-E06AB2E7-201D-4DF0-B56B-F0AB5D9FD86BQ43185204-3877177E-5C71-4BE0-AC3A-D1C0DC0315C0
P2860
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Importance of protease inhibit ...... data from the Viradapt Study.
@ast
Importance of protease inhibit ...... data from the Viradapt Study.
@en
type
label
Importance of protease inhibit ...... data from the Viradapt Study.
@ast
Importance of protease inhibit ...... data from the Viradapt Study.
@en
prefLabel
Importance of protease inhibit ...... data from the Viradapt Study.
@ast
Importance of protease inhibit ...... data from the Viradapt Study.
@en
P2093
P1433
P1476
Importance of protease inhibit ...... data from the Viradapt Study.
@en
P2093
Clevenbergh P
Del Giudice P
Dellamonica P
Garraffo R
Montagne N
Schapiro JM
P304
P356
10.1097/00002030-200007070-00005
P407
P577
2000-07-01T00:00:00Z